Shots:
- Cerevance has reported the P-III (ARISE) trial data assessing solengepras (75 or 150mg, QD, PO) vs PBO as an adjunct to levodopa & other PD medications in 341 PD pts (≥30yrs.) with motor fluctuations & ≥3hrs. of daily OFF time (91% pts completed the trial)
- Solengepras (150mg) met the 1EP, reducing average daily OFF time by 0.61hrs. at Wk. 12, with benefits seen from Wk. 2 through Wk. 12. It also increased ON time without troublesome dyskinesia by 0.60 hrs. (2EP)
- Solengepras (150mg) significantly improved motor experiences of daily living (MDS-UPDRS Part II) by 1.91 points. Daytime sleepiness also improved by 0.98 points on the Epworth Sleepiness Scale, while PDQ-39 QoL scores improved by 2.87 points vs PBO
Ref: Globenewswire | Image: Cerevance | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
